Boston-based Haemonetics will transfer all of its stake in Inlog Holdings France SAS and its subsidiary In Log SAS, which includes several products on the EdgeSuite software platform. The company’s employees will remain employed after the transaction closes, which is expected to take place in the third quarter of calendar year 2020.
“This divestiture and the recent sale of our blood collection software in the United States are helping to reorient our portfolio towards our growth segments,” said Haemonetics President and CEO Chris Simon said in a press release. “The software that supports our growth and industry leadership remains an important part of our innovation agenda.”
In May, Haemonetics announced plans to sell certain blood donor management software assets to the GPI group. Last month, the company also agreed to sell its manufacturing operations in Fajardo, Puerto Rico, to filter maker GVS.